GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Iovance Biotherapeutics Inc (NAS:IOVA) » Definitions » PS Ratio

Iovance Biotherapeutics (Iovance Biotherapeutics) PS Ratio : 1,281.88 (As of May. 17, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Iovance Biotherapeutics PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Iovance Biotherapeutics's share price is $10.255. Iovance Biotherapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.01. Hence, Iovance Biotherapeutics's PS Ratio for today is 1,281.88.

The historical rank and industry rank for Iovance Biotherapeutics's PS Ratio or its related term are showing as below:

IOVA' s PS Ratio Range Over the Past 10 Years
Min: 1110   Med: 2133.33   Max: 7760
Current: 1302.86

During the past 13 years, Iovance Biotherapeutics's highest PS Ratio was 7760.00. The lowest was 1110.00. And the median was 2133.33.

IOVA's PS Ratio is ranked worse than
96.6% of 1000 companies
in the Biotechnology industry
Industry Median: 9.155 vs IOVA: 1302.86

Iovance Biotherapeutics's Revenue per Sharefor the three months ended in Mar. 2024 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.01.

Back to Basics: PS Ratio


Iovance Biotherapeutics PS Ratio Historical Data

The historical data trend for Iovance Biotherapeutics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Iovance Biotherapeutics PS Ratio Chart

Iovance Biotherapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 1,626.00

Iovance Biotherapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 1,516.67 1,626.00 1,852.50

Competitive Comparison of Iovance Biotherapeutics's PS Ratio

For the Biotechnology subindustry, Iovance Biotherapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Iovance Biotherapeutics's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Iovance Biotherapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Iovance Biotherapeutics's PS Ratio falls into.



Iovance Biotherapeutics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Iovance Biotherapeutics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=10.255/0.008
=1,281.88

Iovance Biotherapeutics's Share Price of today is $10.255.
Iovance Biotherapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Iovance Biotherapeutics  (NAS:IOVA) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Iovance Biotherapeutics PS Ratio Related Terms

Thank you for viewing the detailed overview of Iovance Biotherapeutics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Iovance Biotherapeutics (Iovance Biotherapeutics) Business Description

Traded in Other Exchanges
Address
825 Industrial Road, Suite 400, San Carlos, CA, USA, 94070
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approval and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
Executives
Merrill A Mcpeak director PO BOX 500 (M/S 55-985), 14200 SW KARL BRAUN DRIVE, BEAVERTON OR 97077-0001
Wayne P. Rothbaum director C/O QUOGUE CAPITAL LLC, 1285 AVENUE OF THE AMERICAS, 35TH FLOOR, NEW YORK NY 10019
Wendy L Yarno director
Frederick G Vogt officer: General Counsel 2120 HEMLOCK RD., WEST NORRITON PA 19403
Iain D. Dukes director 112 W. 34TH STREET, 17TH FLOOR, NEW YORK NY 10120
Wendy L Dixon director
Ryan D Maynard director RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Michael Weiser director C/O SPACES, SUITE 265, 3350 VIRGINIA STREET, MIAMI FL 33133
Igor Bilinsky officer: Chief Operating Officer C/O VICAL INCORPORATED, 10390 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Jean-marc Bellemin officer: Chief Financial Officer C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
Michael Swartzburg officer: VP, Finance C/O AVALANCHE BIOTECHNOLOGIES, INC., 1035 O'BRIEN DRIVE, SUITE A, MENLO PARK CA 94025
Athena Countouriotis director C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121
Finckenstein Friedrich Graf officer: Chief Medical Officer 999 SKYWAY ROAD, SUITE 150, SAN CARLOS CA 94070
Timothy E Morris officer: Chief Financial Officer ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Maria Fardis director, officer: President and CEO C/O PARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085